HONOLULU, Feb. 27, 2017 -- Attorney Margaret Dore, president of Choice is an Illusion, which is fighting assisted suicide and euthanasia legalization efforts throughout the United States, made the following statement in connection with an assisted suicide/euthanasia bill set for hearing tomorrow in the Hawaii State Senate Committee on Judiciary and Labor. The bill is SB 1129 S.D. 1.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/58967841-09da-4273-934a-f638de752bac
“The bill seeks to pass a proposed act legalizing assisted suicide and allowing euthanasia,” said Dore. “If enacted, the act will apply to people with years or decades to live. The act is a recipe for elder abuse, especially for people with money, meaning the middle class and above in the inheritance situation.”
Dore said, "The proposed act allows the patient's heir, who will financially benefit from the patient's death, to actively participate in requesting the lethal dose. After that, no doctor, not even a witness, is required to be present at the death. Even if the patient struggled, who would know?"
"But, it gets worse," said Dore, "the death certificate is required to list a terminal disease as the cause of death, which prevents prosecution." Dore explained, "The official cause of death is a terminal disease (not murder) as a matter of law. For inheritance perpetrators, the death certificate is a 'stay out of jail free card.'”
Dore stated, “If enacted, the proposed act will legalize assisted suicide and euthanasia for people who are 'terminal,' which is defined as a doctor's prediction of less than six months to live. In real life, such persons may have years or decades to live."
"Doctors can be wrong about life expectancy, sometimes way wrong," said Dore. "This is due to mistakes and the fact that predicting life expectancy is not an exact science. A few years ago, I was met at the airport by a man who at age 18 or 19 had been diagnosed with ALS (Lou Gehrig's disease) and given 3 to 5 years to live, at which time he would die by paralysis. His diagnosis had been confirmed by the Mayo Clinic. When he met me at the airport, he was 74 years old. The disease progression had stopped on its own."
Dore stated, “The proposed act is based on a similar law in Oregon. In Oregon, a young adult with insulin dependent diabetes is ‘terminal’ because the six months to live is determined without treatment. A typical insulin dependent adult will live less than a month without insulin. Such persons are therefore ‘terminal’ for the purpose of assisted suicide.”
Dore added, “By contrast, with insulin, such persons may have decades to years or decades to live.”
Dore concluded, “The proposed act will create the perfect crime and encourage people with years or decades to live to throw away their lives. The act must be rejected.”
For more information, see “Dore Memo Opposing SB 1129 SD1,” which can be viewed at these links: memo and appendix.
Contact: Margaret Dore, Esq., MBA President [email protected] (206) 697-1217


CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Instagram Outage Disrupts Thousands of U.S. Users
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 



